Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder

Annals of Clinical Psychiatry

Volumn 27, Issue 2, 2015, Pages 142-149

  Lam, Raymond W ^a   Parikh, Sagar V ^b   Michalak, Erin E ^a   Dewa, Carolyn S ^b   Kennedy, Sidney H ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; COGNITIVE DEFECT; CONCEPTUAL FRAMEWORK; CONSENSUS; DRUG INDUSTRY; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GOVERNMENT; HAMILTON DEPRESSION RATING SCALE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR DEPRESSION; MEDICAL SOCIETY; METHODOLOGY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; REVIEW; STUDY DESIGN; ADVISORY COMMITTEE; CANADA; DEPRESSIVE DISORDER, MAJOR; STANDARDS;

ADVISORY COMMITTEES; CANADA; CONSENSUS; DEPRESSIVE DISORDER, MAJOR; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC;

EID: 84947056200     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland: WHO Press, 2008.
2. Druss BG, Rosenheck RA, Sledge WH. Health and disability costs of depressive illness in a major U.S. corporation. Am J Psychiatry. 2000;157:1274-1278.
3. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914-919.
4. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851-858.
5. Adler DA, McLaughlin TJ, Rogers WH, et al. Job performance deficits due to depression. Am J Psychiatry. 2006;163:1569-1576.
6. Weissman MM. Social functioning and the treatment of depression. J Clin Psychiatry. 2000;61(suppl 1):33-38.
7. Moore DJ, Moseley S, Atkinson JH. The influence of depression on cognition and daily functioning. In: Marcotte TD, Grant I, eds. Neuropsychology of everyday functioning. New York, NY: Guilford Press; 2010:419-440.
8. Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000;17:13-35.
9. Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry. 2006;163:148-150.
10. Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010;24:267-284.
11. Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011;132(suppl 1):S9-S13.
12. Langlieb AM, Guico-Pabia CJ. Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12. doi: 10.4088/PCC.09r00826blu.
13. Bech P. Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs. 2005;19:313-324.
14. Kennedy N, Foy K, Sherazi R, et al. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007;9:25-37.
15. Beck A, Crain AL, Solberg LI, et al. Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011;9:305-311.
16. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am. 2002;25:685-698.
17. Asche CV, Joish VN, Camacho F, et al. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. Curr Med Res Opin. 2010;26:1843-1853.
18. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004;65(suppl 16):27-32.
19. Wisniewski SR, Rush AJ, Bryan C, et al. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007;195:219-225.
20. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-855.
21. McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29:243-259.
22. Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. J Affect Disord. 2009;117:S1-S64.
23. Berardi D, Berti Ceroni G, Leggieri G, et al. Mental, physical and functional status in primary care attenders. Int J Psychiatry Med. 1999;29:133-148.
24. Mondloch MV, Cole DC, Frank JW. Does how you do depend on how you think you'll do? A systematic review of the evidence for a relation between patients' recovery expectations and health outcomes. CMAJ. 2001;165:174-179.
25. Baum CM, Katz N. Occupational therapy approach to assessing the relationship between cognition and function. In: Marcotte TD, Grant I, eds. Neuropsychology of everyday functioning. New York, NY: Guilford Press; 2010:62-90.
26. Faerden A, Nesvåg R, Marder SR. Definitions of the term 'recovered' in schizophrenia and other disorders. Psychopathology. 2008;41:271-278.
27. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol. 2001;1:2.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
29. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
30. Barton KN. Health Canada Regulatory Considerations for Functional Outcomes in Depression. Plenary session at the CANMAT Consensus Statement Conference on Functional Outcomes in Depression Clinical Trials; February 10, 2012; Ottawa, ON, Canada.
31. European Agency for the Evaluation of Medicinal Products. Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003526.pdf. Published 2002. Accessed April 12, 2011.
32. U.S. Department of Health and Human Services-Food and Drug Administration. Description of the Hamilton Depression Rating Scale (HAMD) and the Montgomery-Asberg Depression Rating Scale (MADRS). http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4273b1-04-descriptionofmadrshamddepressionr%281%29.pdf. Published 2007. Accessed April 12, 2011.
33. Gotlib IH, Joormann J. Cognition and depression: current status and future directions. Annu Rev Clin Psychol. 2010;6:285-312.
34. Carswell A, McColl MA, Baptiste S, et al. The Canadian Occupational Performance Measure: a research and clinical literature review. Can J Occup Ther. 2004;71:210-222.
35. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27:93-105.
36. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-771.
37. Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol. 1997;7(suppl 1):S57-S70; discussion S71-S71.
38. Weissman MM, MHS Staff. Social Adjustment Scale-Self Report (SAS-SR): User's Manual. North Tonwanda, NY/Toronto, ON, Canada: Multi-Health Systems Inc; 1999.
39. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
40. World Health Organization. WHO psychiatric disability assessment schedule (WHO/DAS): with a guide to its use. Geneva, Switzerland: WHO Press; 1988.
41. Kessler RC, Barber C, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45:156-174.
42. Endicott J, Nee J. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull. 1997;33:13-16.
43. Lam RW, Michalak EE, Yatham LN. A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. BMC Psychiatry. 2009;9:78.
44. Koopman C, Pelletier KR, Murray JF,et al. Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med. 2002;44:14-20.
45. Lerner D, Amick BC 3rd, Rogers WH, et al. The work limitations questionnaire. Med Care. 2001;39:72-85.
46. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353-365.
47. Mundt JC, Marks IM, Shear MK, et al. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461-464.
48. Moore DJ, Palmer BW, Patterson TL, et al. A review of performance-based measures of functional living skills. J Psychiatr Res. 2007;41:97-118.
49. Frost MH, Reeve BB, Liepa AM, et al. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value in Health. 2007;10(suppl 2):S94-S105.
50. U.S. Department of Health and Human Services - Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Published December 2009. Accessed February 20, 2015.
51. Scoggins JF, Patrick DL. The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials. 2009;30:289-292.
52. Carter JD, Frampton CM, Mulder RT, et al. The relationship of demographic, clinical, cognitive and personality variables to the discrepancy between self and clinician rated depression. J Affect Disord. 2010;124:202-206.
53. Copay AG, Subach BR, Glassman SD, et al. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7:541-546.
54. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395-407.
55. Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70.
56. Abma FI, van der Klink JJ, Terwee CB, et al. Evaluation of the measurement properties of self-reported health-related work-functioning instruments among workers with common mental disorders. Scand J Work Environ Health. 2012;38:5-18.
57. Backenstrass M, Frank A, Joest K, et al. A comparative study of nonspecific depressive symptoms and minor depression regarding functional impairment and associated characteristics in primary care. Compr Psychiatry. 2006;47:35-41.
58. Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry. 2009;70(suppl 6):26-31.
59. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88(suppl 2):S61-S71.
60. Davidson L, Drake RE, Schmutte T, et al. Oil and water or oil and vinegar? Evidence-based medicine meets recovery. Community Ment Health J. 2009;45:323-332.
61. Scott SD, Albrecht L, O'Leary K, et al. A protocol for a systematic review of knowledge translation strategies in the allied health professions. Implement Sci. 2011;6:58.
62. Canadian Institutes of Health Research. Innovation in Action: The CIHR Knowledge Translation Strategy 2004-2009. Ottawa, ON, Canada: Government of Canada; 2004.
63. World Health Organization. Bridging the "know-do" gap: meeting on knowledge translation in global health. Geneva, Switzerland: WHO Press; 2006.
64. Diagnostic and statistical manual of mental disorders, 5th edition. Washington, DC: American Psychiatric Association; 2013.
65. Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry. 2001;62(suppl 26):5-9.
66. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289:3152-3160.
67. Kelsey JE. Clinician perspective on achieving and maintaining remission in depression. J Clin Psychiatry. 2001;62(suppl 26):16-21.